Esperion Therapeutics SCREAMS Short Selling Scheme
$Esperion Therapeutics (ESPR.US)$ Undervalued Stock with a Game-Changing Statin Alternative
This is a $0.73 stock with a market cap of approximately $145 million — offering significant upside potential. The company, Esperion Therapeutics, sells two FDA-approved, much-needed statin alternatives: Nexletol and Nexlizet. These medications address a major health need — millions of patients cannot tolerate statins due to side effects but still need to manage their cholesterol and cardiovascular risk. (Reminder: get your cholesterol and inflammation markers like hsCRP checked.)
About the Drugs – Nexletol & Nexlizet:
– Once-daily oral pills — more convenient than injectable alternatives.
– Proven to lower LDL cholesterol by up to 38%, with many patients experiencing reductions of 44–50%.
– Lowers hsCRP (inflammation marker) by up to 36% — something no other statin alternative does.
◦ No muscle pain, weakness, or fatigue — common side effects that lead patients to quit statins.
◦ No increased risk of insulin resistance or type 2 diabetes, unlike high-intensity statins.
– Safer than statins:
Real-world outcomes:
– My sister saw a 44% LDL reduction on Nexlizet.
– A friend suffered a stroke despite normal cholesterol levels, but had elevated hsCRP, underscoring the importance of inflammation control.
Competing with Giants
Esperion is directly competing with Amgen (AMGN), which sells Repatha, an injectable PCSK9 inhibitor that lowers LDL by 55%.
– Repatha does over $1.25 billion in U.S. sales annually.
– By comparison, Esperion is on track to generate $168 million in revenue this year, with forecasts of $250 million next year — showing rapid growth and massive catch-up potential.
– Nexlizet offers a more affordable, oral alternative, with a similar efficacy range for many patients and the unique benefit of reducing inflammation (hsCRP).
Financial Outlook
– Sales growing at over 50% annually.
– Profitability expected by end of 2025.
– Trading at a fraction of its potential market valuation, considering product performance and market size.
Evidence of Stock Manipulation — "Short and Distort" in Action?
There are growing signs that Esperion’s stock is being manipulated lower through a classic “short and distort” scheme. This type of manipulation creates panic selling and artificially depresses the stock price — potentially to enable accumulation at a discount ahead of a future acquisition.
Manipulating stock prices lower through coordinated transactions and online fear-mongering is a known form of market manipulation, often referred to as a "short and distort" scheme. Here’s a detailed breakdown of how this manipulation works, specifically focusing on inter-account transactions and message board tactics:
1. Short Selling Basics
– Short sellers borrow shares and sell them at the current price, hoping to buy them back later at a lower price.
– Profit is made if the stock drops in price.
2. Manipulative Inter-Account Transactions
This involves creating the illusion of high-volume selling or low demand using controlled or coordinated accounts.
Tactics include:
◦ Creates artificial volume and downward price pressure.
◦ Appears as “real” selling, influencing others to sell in panic.
– Wash Trading: An entity sells shares from one account and buys them back in another account they control.
– Spoofing or Layering (illegal): Placing large sell orders to create pressure, then canceling them after prices move.
◦ Can mislead market participants into thinking the price is collapsing.
– Cross Trades: Pre-arranged trades between accounts at lower prices.
3. Fear, Uncertainty, and Doubt (FUD) on Message Boards
While manipulating trades, the perpetrators amplify fear through social and digital channels:
Common Tactics:
◦ Posting rumors about insolvency, lawsuits, insider selling, or regulatory actions.
◦ Pretending to be insiders, whistleblowers, or concerned shareholders.
– Spreading False Information:
◦ Highlighting normal business risks as catastrophic.
◦ Posting doctored screenshots or misrepresenting company filings.
– Creating Panic Narratives:
◦ Multiple coordinated accounts reinforce each other's messages.
◦ Gives the illusion of widespread concern or insider knowledge.
– Swarms of Anonymous Accounts (Sock Puppets):
◦ Dismissing or mocking optimistic posts to stifle bullish discussion.
◦ Accusing bullish posters of being shills or pumpers.
– Attacking Positive Sentiment:
4. The Result: Downward Spiral
– Retail investors panic and sell, increasing downward momentum.
– Algorithms and institutional investors may join in due to price/volume signals.
– Short sellers profit by buying back at the new, lower price.
5. Legal and Regulatory View
– These activities are illegal under SEC rules (e.g., Rule 10b-5 against fraud and manipulation).
– The SEC, FINRA, and DOJ have taken enforcement actions against such schemes in the past.
Example Case:**
– In the early 2000s, some hedge funds were accused of colluding with message board posters and using naked short selling alongside fear tactics to crash small-cap stocks.
– More recently, the GameStop (GME) saga exposed alleged manipulations on both sides — though hard to prove intent, coordinated behavior was widely suspected.
Summary
Manipulation occurs when traders create artificial selling pressure through controlled transactions, while simultaneously using online forums to amplify fear and uncertainty. This combo can cause real investors to panic and sell, giving manipulators a profit on their short positions.
The Bottom Line
Esperion is a dramatically undervalued company offering life-saving drugs in a multibillion-dollar market. With superior convenience, safety, and growing adoption, Nexlizet and Nexletol could become leading choices for statin-intolerant patients.
As revenue accelerates and the market wakes up to this opportunity, there’s significant upside — both in terms of patient impact and shareholder value
Esperion just needs Wallstreet Bets and Roaring Kitty to do real research on this Amazing and much NEEDED Drug Nexlizet. $GameStop (GME.US)$ was EPIC.
I own or trade $AMC Entertainment (AMC.US)$ $Plug Power (PLUG.US)$ $BigBear.ai Holdings (BBAI.US)$ $SoundHound AI (SOUN.US)$ $Palantir (PLTR.US)$ $Carvana (CVNA.US)$ $Amazon (AMZN.US)$ $eBay (EBAY.US)$ $Hims & Hers Health (HIMS.US)$ $Intuitive Machines (LUNR.US)$ $Pinterest (PINS.US)$ $Chewy (CHWY.US)$ $Gorilla Technology (GRRR.US)$ $Oracle (ORCL.US)$ $NVIDIA (NVDA.US)$ DID so well > $Super Micro Computer (SMCI.US)$ $Advanced Micro Devices (AMD.US)$ $Netflix (NFLX.US)$
Email my hedge fund contact sent to the CEO of Hims: andrew@forhims.com
Subject: Strategic Collaboration Opportunity: Hims & Esperion Therapeutics – Unlocking the Future of Statin Alternatives
Hi Andrew,
I hope you’re doing well. As a Hims shareholder and strong believer in your mission to reshape modern healthcare, I wanted to share an exciting opportunity to expand Hims’ reach into cardiometabolic and preventive care: a potential collaboration with Esperion Therapeutics, the developers of NEXLIZET® and NEXLETOL®, two unique FDA-approved, non-statin cholesterol-lowering drugs.
First and Only Statin Alternatives Approved for Primary Prevention
In 2024, the FDA approved NEXLIZET and NEXLETOL as the ONLY non-statin therapies with a label for PRIMARY PREVENTION of cardiovascular disease.
This is a game-changer for patients who can’t tolerate statins or want to avoid their metabolic risks.
This is a game-changer for patients who can’t tolerate statins or want to avoid their metabolic risks.
The Only Non-Statins That Lower Inflammation (hsCRP)
Beyond lowering LDL-C, NEXLIZET and NEXLETOL also reduce hsCRP (high-sensitivity C-reactive protein)—a critical marker of vascular inflammation that contributes to heart attacks and strokes.
hsCRP reduction data:
– NEXLIZET: up to 36.7%
– NEXLETOL: reductions from 25% to 29%
– By comparison, ezetimibe alone showed significantly less effect, and PCSK9 inhibitors like Repatha do not reduce hsCRP at all
A friend of mine, Peter, was on Repatha and had excellent LDL-C reduction (~55%), but still suffered a stroke due to persistently high hsCRP.
This proves that LDL reduction alone isn't enough—inflammation matters.
Real-World Results:
– A retired Marine I know saw a 42.3% LDL-C reduction in just 6 months on NEXLIZET—with no dietary or exercise changes.
– A retired law enforcement officer saw a 53% reduction.
– Both had no side effects and are thriving on the medication.
Statins: Still a Major Risk for Millions
– 30% of patients experience muscle pain
–
Statins raise blood sugar and insulin resistance, pushing many prediabetics into TYPE 2 DIABETES
– Other unwanted side effects include fatigue, memory issues, erectile dysfunction, and depression
Trusted Expert Support: Dr. Peter Attia
Dr. Peter Attia, a leading figure in preventive and longevity medicine, shared on his podcast that he stopped taking statins and now takes NEXLIZET.
He highlights that bempedoic acid is a prodrug activated only in the liver, leading to:
He highlights that bempedoic acid is a prodrug activated only in the liver, leading to:
– No muscle pain
– No elevation in blood sugar
– No systemic side effects
See his deep dive on YouTube: “Peter Attia Dives Deep on Statins” — skip to minute 25 for his insights on why he trusts NEXLIZET.
Commercial Pitch Concept:
“Taking a statin and feeling muscle pain? Low energy? Worried about diabetes?
Try NEXLIZET—the side-effect-free statin alternative you can trust.”
Hims’ consumer-first approach is a perfect match to deliver this message at scale to the millions looking for safer cholesterol solutions.
What’s Coming: Triple Combo Pill (by 2027)
Esperion is working on a once-daily pill combining bempedoic acid, ezetimibe, and a low-dose statin—expected to reduce LDL-C by up to 65%.
Because all three drugs are already used together clinically, FDA approval is anticipated by 2027.
Because all three drugs are already used together clinically, FDA approval is anticipated by 2027.
Hundreds of Millions in Potential Profit
With cholesterol-lowering drugs among the most prescribed worldwide, this could represent a massive growth opportunity for Hims to enter a new, scalable market—while solving a widespread patient pain point.
I don’t have a direct contact at Esperion, but I’d be happy to share more details or connect you with real patients on NEXLIZET who are willing to share lab results and their transformative experiences.
Thanks for considering this.
Warm regards,
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Market Insights
Popular Gold Mining Stocks Popular Gold Mining Stocks
Amidst the uncertain outlook of the trade war and escalating concerns about an economic recession, gold prices have repeatedly reached new highs this year, at one point surpassing $3,500 per ounce. This marks an almost 30% increase since the beginning of the year. For investors in U.S. equities, investing in gold mining stocks represents a significant opportunity to ride this wave. Amidst the uncertain outlook of the trade war and escalating concerns about an economic recession, gold prices have repeatedly reached new highs this year, at one point surpassing $3,500 per ounce. This marks an almost 30% increase since the beginning of the year. For investors in U.S. equities, investing in gold mining stocks represents a significant opportunity to ride this wave.
Unlock Now
Discussing
Gold has rebounded to $3,300! It's time to get on board?
🎙️ Discussion: 1. Has it $Gold Futures (AUG5) (GCmain.US)$ rebounded to $3,300? Will the short-term trend continue to rise? 2. What factors
Options Newsman
May 6 20:45
S&P 500's Put/Call Ratio Hits 5-Year Low: Fear Fades and Bottom Near?
103475232 : more than 10x stock, HIMS will buy for further
103475232 : All in , retirement fund
74502850 : Well written and some good facts. We continue to prescribe Nexlizet 1st before PCSK9 injections and that will help the company catch up to Repatha sales. The beauty is Nexlizet is a once a day pill and provides an extra layer of protection by lowering hscrp, sadly PCSK9 injections don't. (972)-649-6511. Heartplace Texas.
DazzlerAus : also trading at close to cash at hand value can't go too much lower you would think
Growth Investor27 : $110 MILLION to $130 MILLION being paid to ESPR this year in milestones from Otsuka, with royalties starting next year at 15% and Canada, Australia & Israel and New Zealend. Then all the royalties diverting back to Esperion from Daiichi Sankyo by 2028 Q3 estimate, bring in $200 million a year by then. Patents extended to 2040. And Triple combo single pill with a statin bring down LDL by 65% is HUGE. The Only STATIN alternative that lowers HSCRP to give additional layer of protection from a HEART ATTACK & STROKE. This stock is crazy undervalued. LOAD & Hold. I take the NEXLIZET myself and have great results with NO side effects.
Cashcauterize Growth Investor27 : Nice
Yi S : Wake up, take a look at the company's Market Cap, it's just a small amount!
102948779 : This is falling knife stock beware
The price tell the truth 妖股